Alto Neuroscience (NYSE:ANRO) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Alto Neuroscience (NYSE:ANRO) from a strong sell rating to a hold rating in a research note released on Thursday morning,Zacks.com reports.

Several other research firms also recently weighed in on ANRO. Chardan Capital reiterated a “buy” rating and set a $30.00 price target on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Wolfe Research started coverage on Alto Neuroscience in a research report on Friday, May 22nd. They issued an “outperform” rating on the stock. BTIG Research increased their price target on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Wall Street Zen upgraded shares of Alto Neuroscience from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Wedbush raised their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and an average price target of $37.25.

Alto Neuroscience Trading Up 0.3%

NYSE:ANRO opened at $34.36 on Thursday. The company has a market capitalization of $1.35 billion, a P/E ratio of -14.20 and a beta of 1.06. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a 12 month low of $3.41 and a 12 month high of $35.41. The firm has a fifty day simple moving average of $27.36 and a 200-day simple moving average of $23.39.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08. On average, equities research analysts anticipate that Alto Neuroscience will post -2.68 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. AQR Capital Management LLC purchased a new stake in shares of Alto Neuroscience during the 1st quarter worth about $52,000. Torren Management LLC purchased a new position in shares of Alto Neuroscience in the 4th quarter valued at about $62,000. Invesco Ltd. purchased a new position in shares of Alto Neuroscience in the 1st quarter valued at about $67,000. Bridgeway Capital Management LLC raised its holdings in Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after purchasing an additional 25,000 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in Alto Neuroscience in the 4th quarter worth about $198,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.